BRPI1011875A2 - compostos n-fenil-(piperazinil ou homopiperazinil)-benzenosulfonamida ou benzenosulfonil-fenil-(piperazina ou homopiperazina) adequados para tratamento de distúrbios que respondem à modulação do receptor 5-ht6 de serotonina - Google Patents

compostos n-fenil-(piperazinil ou homopiperazinil)-benzenosulfonamida ou benzenosulfonil-fenil-(piperazina ou homopiperazina) adequados para tratamento de distúrbios que respondem à modulação do receptor 5-ht6 de serotonina

Info

Publication number
BRPI1011875A2
BRPI1011875A2 BRPI1011875A BRPI1011875A BRPI1011875A2 BR PI1011875 A2 BRPI1011875 A2 BR PI1011875A2 BR PI1011875 A BRPI1011875 A BR PI1011875A BR PI1011875 A BRPI1011875 A BR PI1011875A BR PI1011875 A2 BRPI1011875 A2 BR PI1011875A2
Authority
BR
Brazil
Prior art keywords
phenyl
homopiperazine
homopiperazinyl
benzenesulfonamide
benzenesulfonyl
Prior art date
Application number
BRPI1011875A
Other languages
English (en)
Inventor
Relo Ana-Lucia
Haupt Andreas
Bespalov Anton
Vogg Barbara
Pohlki Frauke
Backfisch Gisela
Delzer Juergen
Drescher Karla
Wicke Karsten
Unger Liliane
Zhang Min
Lao Yanbin
Original Assignee
Abbott Gmbh & Co Kg
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42236832&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI1011875(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Abbott Gmbh & Co Kg, Abbott Lab filed Critical Abbott Gmbh & Co Kg
Publication of BRPI1011875A2 publication Critical patent/BRPI1011875A2/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D295/00Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/096Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D241/00Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/04Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D243/00Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/08Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 not condensed with other rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D317/00Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurosurgery (AREA)
  • General Health & Medical Sciences (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Addiction (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
BRPI1011875A 2009-04-30 2010-04-29 compostos n-fenil-(piperazinil ou homopiperazinil)-benzenosulfonamida ou benzenosulfonil-fenil-(piperazina ou homopiperazina) adequados para tratamento de distúrbios que respondem à modulação do receptor 5-ht6 de serotonina BRPI1011875A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US17405409P 2009-04-30 2009-04-30
PCT/EP2010/055789 WO2010125134A1 (en) 2009-04-30 2010-04-29 N-phenyl-(piperazinyl or homopiperazinyl)-benzenesulfonamide or benzenesulfonyl-phenyl-(piperazine or homopiperazine) compounds suitable for treating disorders that respond to modulation of the serotonin 5-ht6 receptor

Publications (1)

Publication Number Publication Date
BRPI1011875A2 true BRPI1011875A2 (pt) 2018-06-19

Family

ID=42236832

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI1011875A BRPI1011875A2 (pt) 2009-04-30 2010-04-29 compostos n-fenil-(piperazinil ou homopiperazinil)-benzenosulfonamida ou benzenosulfonil-fenil-(piperazina ou homopiperazina) adequados para tratamento de distúrbios que respondem à modulação do receptor 5-ht6 de serotonina

Country Status (26)

Country Link
US (1) US8076326B2 (pt)
EP (1) EP2432769B1 (pt)
JP (1) JP5718898B2 (pt)
KR (1) KR20120016639A (pt)
CN (1) CN102459197B (pt)
AR (1) AR076507A1 (pt)
AU (1) AU2010243585B2 (pt)
BR (1) BRPI1011875A2 (pt)
CA (1) CA2759482A1 (pt)
CL (1) CL2011002653A1 (pt)
CO (1) CO6450637A2 (pt)
CR (1) CR20110604A (pt)
DO (1) DOP2011000326A (pt)
EC (1) ECSP11011468A (pt)
ES (1) ES2536779T3 (pt)
IL (1) IL215642A (pt)
MX (1) MX2011011520A (pt)
NZ (1) NZ595698A (pt)
PE (1) PE20120881A1 (pt)
RU (1) RU2535200C2 (pt)
SG (1) SG175187A1 (pt)
TW (1) TWI465438B (pt)
UA (1) UA107080C2 (pt)
UY (1) UY32604A (pt)
WO (1) WO2010125134A1 (pt)
ZA (1) ZA201107569B (pt)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009147189A1 (en) 2008-06-05 2009-12-10 Glaxo Group Limited Novel compounds
WO2009147188A1 (en) 2008-06-05 2009-12-10 Glaxo Group Limited Benzpyrazol derivatives as inhibitors of pi3 kinases
ES2383246T3 (es) 2008-06-05 2012-06-19 Glaxo Group Limited 4-amino-indazoles
JP5656880B2 (ja) 2009-03-09 2015-01-21 グラクソ グループ リミテッドGlaxo Group Limited Pi3キナーゼの阻害剤としての4−オキサジアゾール−2−イル−インダゾール
LT2899191T (lt) 2009-04-30 2017-10-25 Glaxo Group Limited Oksazolo pakeistieji indazolai kaip pi3-kinazės inhibitoriai
US8343959B2 (en) * 2009-04-30 2013-01-01 Abbott Gmbh & Co. Kg N-phenyl-(piperazinyl or homopiperazinyl)-benzenesulfonamide or benzenesulfonyl-phenyl-(piperazine or homopiperazine) compounds suitable for treating disorders that respond to modulation of the serotonin 5-HT6 receptor
GB201018124D0 (en) 2010-10-27 2010-12-08 Glaxo Group Ltd Polymorphs and salts
WO2012059432A1 (en) * 2010-11-01 2012-05-10 Abbott Gmbh & Co. Kg N-phenyl-(homo)piperazinyl-benzenesulfonyl or benzenesulfonamide compounds suitable for treating disorders that respond to the modulation of the 5-ht6 receptor
US20140120036A1 (en) * 2012-01-06 2014-05-01 Abbvie Inc. Radiolabeled 5-ht6 ligands
KR20150092764A (ko) * 2012-12-10 2015-08-13 에프. 호프만-라 로슈 아게 RORc 조절인자로서의 벤질 설폰아마이드 유도체
CN105121404A (zh) * 2013-03-15 2015-12-02 豪夫迈·罗氏有限公司 作为RORc调节剂的芳基磺酰胺和氨基磺酸衍生物
EP3083588B1 (en) 2013-12-20 2020-12-09 Sunshine Lake Pharma Co., Ltd. Aromatic heterocyclic compounds and their application in pharmaceuticals
US9840482B2 (en) 2014-04-19 2017-12-12 Sunshine Lake Pharma Co., Ltd. Sulfonamide derivatives and pharmaceutical applications thereof
US20250228851A1 (en) * 2021-10-20 2025-07-17 Yousef Najajreh Allosteric inhibitor compounds for overcoming cancer resistance

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DZ2376A1 (fr) 1996-12-19 2002-12-28 Smithkline Beecham Plc Dérivés de sulfonamides nouveaux procédé pour leurpréparation et compositions pharmaceutiques les c ontenant.
EP0994862B1 (en) * 1997-07-11 2005-06-01 SmithKline Beecham plc Sulphonamide derivatives being 5-ht6 receptor antagonists and process for their preparation
GB9818916D0 (en) 1998-08-28 1998-10-21 Smithkline Beecham Plc Use
GB9818914D0 (en) 1998-08-28 1998-10-21 Smithkline Beecham Plc Use
SE0002739D0 (sv) 2000-07-21 2000-07-21 Pharmacia & Upjohn Ab New use
EP1406884A1 (en) 2001-05-11 2004-04-14 Biovitrum Ab Arylsusfonamide compounds for the treatment of obesity, type ii diabetes and cns-disorders
CN1800185A (zh) * 2001-06-11 2006-07-12 比奥维特罗姆股份公司 取代的磺酰胺化合物、其制备方法及其作为治疗cns疾病、肥胖和ii型糖尿病的药物的应用
MXPA04001250A (es) * 2001-08-10 2004-05-27 Hoffmann La Roche Derivados de arilsulfonilo con afinidad receptora de 5-hidroxitriptamina6 (5-ht6).
JP4467307B2 (ja) * 2002-02-22 2010-05-26 ファルマシア・アンド・アップジョン・カンパニー・エルエルシー 5−ht受容体アンタゴニストとしてのピリジルスルホン誘導体
GB0305575D0 (en) 2003-03-11 2003-04-16 Glaxo Group Ltd Novel compounds
PE20060574A1 (es) 2004-07-28 2006-06-24 Glaxo Group Ltd Derivados de arilpiperazina sulfonamida como agonistas de los receptores de secretagogos de la hormona del crecimiento (ghs)
GB0419192D0 (en) * 2004-08-27 2004-09-29 Merck Sharp & Dohme Therapeutic agents
JP2009533325A (ja) * 2006-03-17 2009-09-17 アストラゼネカ・アクチエボラーグ 5−ht6調節剤としての新規なテトラリン
BRPI0710177A2 (pt) * 2006-04-19 2012-05-29 Abbott Gmbh & Co Kg arilsulfonas heterocìclicas adequadas para tratar distúrbios que respondem à modulação do receptor 5ht6 de serotonina
WO2008087123A2 (en) 2007-01-16 2008-07-24 Solvay Pharmaceuticals B.V. Use of 5-ht6 antagonists to prevent relapse into addiction

Also Published As

Publication number Publication date
KR20120016639A (ko) 2012-02-24
CL2011002653A1 (es) 2012-06-15
ES2536779T3 (es) 2015-05-28
IL215642A (en) 2015-09-24
UA107080C2 (uk) 2014-11-25
RU2535200C2 (ru) 2014-12-10
TWI465438B (zh) 2014-12-21
ECSP11011468A (es) 2011-12-30
TW201043606A (en) 2010-12-16
UY32604A (es) 2010-12-31
US8076326B2 (en) 2011-12-13
CN102459197B (zh) 2015-08-19
CO6450637A2 (es) 2012-05-31
DOP2011000326A (es) 2011-11-15
MX2011011520A (es) 2012-06-19
HK1163104A1 (zh) 2012-09-07
US20100280014A1 (en) 2010-11-04
AU2010243585A1 (en) 2011-11-17
CN102459197A (zh) 2012-05-16
CR20110604A (es) 2012-05-28
EP2432769B1 (en) 2015-04-01
IL215642A0 (en) 2012-01-31
PE20120881A1 (es) 2012-08-24
ZA201107569B (en) 2013-04-24
WO2010125134A1 (en) 2010-11-04
RU2011148583A (ru) 2013-06-10
AR076507A1 (es) 2011-06-15
EP2432769A1 (en) 2012-03-28
SG175187A1 (en) 2011-11-28
NZ595698A (en) 2014-01-31
JP2012525354A (ja) 2012-10-22
AU2010243585B2 (en) 2014-08-07
CA2759482A1 (en) 2010-11-04
JP5718898B2 (ja) 2015-05-13

Similar Documents

Publication Publication Date Title
BRPI1011875A2 (pt) compostos n-fenil-(piperazinil ou homopiperazinil)-benzenosulfonamida ou benzenosulfonil-fenil-(piperazina ou homopiperazina) adequados para tratamento de distúrbios que respondem à modulação do receptor 5-ht6 de serotonina
BRPI0812853A2 (pt) Compostos de quinolina adequados para tratar distúrbios que respondem à modulação do receptor 5-ht6 de serotonina.
CL2013000380A1 (es) Compuestos heterociclicos derivados de [1,2,4] tiadiazina, moduladores positivos del receptor de ampa; medicamento que los contiene; y su uso para la prevencion o el tratamiento de depresion, enfermedad de alzheimer, esquizofrenia o trastorno de hiperactividad de deficit de atencion.
CO7000771A2 (es) Proceso para la fabricación de 1-[2-(2,4-dimetilsulfanil)fenil]piperazina
ECSP088961A (es) Nuevos herbicidas
CO7091184A2 (es) Agentes para tratar trastornos que implican la modulación de receptores de riandonina
BRPI0814180A2 (pt) Método para reduzir os sintomas de, ou para tratar, um ou mais distúrbios nos quais o sistema dopaminérgico está desregulado
BRPI0912362A2 (pt) antagonista do receptor nmda para o tratamento de transtornos neuropsiquiátricos
BR112013031551A2 (pt) aparelhos de lâmpada de descarga de ultravioleta com um ou mais refletores e sistemas os quais determinam os parâmetros de operação e as programações de desinfecção para dispositivos germicidas.
EP2809322A4 (en) COMPOUNDS FOR THE TREATMENT OF SPINAL MUSCLE ATROPHY
CL2015002434A1 (es) Moduladores benzoimidazol-2-il pirimidinas del receptor h4 de histamina.
BRPI1014994A2 (pt) 2,4-diamino pirimidinas para o tratamento de doenças caracterizadas por proliferação excessiva ou anormal de células
PT2838539T (pt) Derivados estrogénicos para utilização no tratamento de distúrbios neurológicos.
EP2958522A4 (en) ANATOMIC GUIDED INSTRUMENTS FOR TROCHLEAFURCHENERSATZ
CL2014000852A1 (es) Proteína de fusión que comprende dominio extracelular de la proteina humana del receptor humano notch1; composicion que la comprende.
BRPI0809081A2 (pt) compostos de quinolina adequados para tratamento de distúrbios que respondem á modulação do receptor da serotonina 5-ht6
CL2008000429A1 (es) Compuestos derivados de heterociclos condensados; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar afecciones asociadas con los receptores alfa2c adrenergicos, tales como congestion asociada a rinitis, polipos, resfrio
EP3390369A4 (en) SOLID FORMS OF SUBSTITUTED 5,6-DIHYDRO-6-PHENYLBENZO [F] ISOQUINOLIN-2-AMINE COMPOUNDS
BRPI0819233A2 (pt) compostos de benzenossulfonanilida adequadas para tratar distúrbios que respondem à modulação do receptor 5-ht6 de serotonina
BR112017024745A2 (pt) compostos e métodos para modulação de receptores de serotonina na periferia.
BRPI0923862A2 (pt) Compostos sulfonamida para o tratamento de distúrbios respiratórios
BR112012004988A2 (pt) compostos para tratar transtornos ou doenças associadas com atividade do receptor de neuroquinina 2
ES1073254Y (es) Electrovalvula para la regulacion de fluidos
ES1176384Y (es) Sistema para la gestión integral de desechos domésticos
ES1065747Y (es) Pieza de union central para mosquiteras

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2477 DE 26-06-2018 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.

B25B Requested transfer of rights rejected

Owner name: ABBOTT GMBH AND CO. KG (DE) ; ABBOTT LABORATORIES

Free format text: INDEFERIDO O PEDIDO DE TRANSFERENCIA CONTIDO NA PETICAO 860140107624 DE 01/07/2014EM VIRTUDE DO DESPACHO PUBLICADO NA RPI NO 2494 DE 23/10/2018.